Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 28, 2024 07:10 ET
|
Royalty Pharma plc
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented...
Key information relating to the cash dividend to be paid by Golar LNG Limited (Ticker: GLNG)
May 28, 2024 07:06 ET
|
Golar LNG
Reference is made to the first quarter 2024 report released on May 28, 2024. Golar LNG Limited (“Golar”), NASDAQ ticker: GLNG, has declared a total dividend of $0.25 per share to be paid on or around...
Golar LNG Limited Interim results for the period ended March 31 2024
May 28, 2024 07:03 ET
|
Golar LNG
Highlights and subsequent events Golar LNG Limited (“Golar” or “the Company”) reports Q1 2024 (“Q1” or “the quarter”) Net income attributable to Golar of $55 million inclusive of $6 million of...
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress
May 28, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate...
Olema Oncology to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:03 ET
|
Olema Oncology
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024 07:02 ET
|
Allakos Inc.
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the...
Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent un taux de réponse important et un profil d’innocuité favorable dans le traitement de première ligne du CETC r/m
May 28, 2024 07:00 ET
|
Merus N.V.
Taux de réponse de 67 % observé chez les 24 patients évaluables Conférence téléphonique le mardi 28 mai à 8 h, heure de l’Est UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 28 mai 2024 (GLOBE...
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
FactSet Schedules Third Quarter 2024 Earnings Call
May 28, 2024 07:00 ET
|
FactSet Research Systems Inc.
NORWALK, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, announced today that it will release its...